149 related articles for article (PubMed ID: 15182827)
1. Adult acute lymphoblastic leukaemia.
Bassan R; Gatta G; Tondini C; Willemze R
Crit Rev Oncol Hematol; 2004 Jun; 50(3):223-61. PubMed ID: 15182827
[TBL] [Abstract][Full Text] [Related]
2. Treatment of adult acute lymphoblastic leukemia.
Gökbuget N; Hoelzer D
Semin Hematol; 2009 Jan; 46(1):64-75. PubMed ID: 19100369
[TBL] [Abstract][Full Text] [Related]
3. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
4. Optimal management of adults with ALL.
Rowe JM
Br J Haematol; 2009 Feb; 144(4):468-83. PubMed ID: 19055668
[TBL] [Abstract][Full Text] [Related]
5. The biology and therapy of adult acute lymphoblastic leukemia.
Faderl S; Jeha S; Kantarjian HM
Cancer; 2003 Oct; 98(7):1337-54. PubMed ID: 14508819
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
7. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
Fuster JL; Bermúdez M; Galera A; Llinares ME; Calle D; Ortuño FJ
Haematologica; 2007 Dec; 92(12):1723-4. PubMed ID: 18056006
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of adult acute lymphoblastic leukemia].
Gökbuget N; Arnold R; Büchner T; Freund M; Gassmann W; Heil G; Hiddemann W; Löffler H; Lipp T; Ludwig WD; Maschmeyer G; Thiel E; Messerer D; Hoelzer D
Praxis (Bern 1994); 1999 Mar; 88(10):407-20. PubMed ID: 10199213
[TBL] [Abstract][Full Text] [Related]
10. Progress in the treatment of adults with acute lymphoblastic leukemia.
Larson S; Stock W
Curr Opin Hematol; 2008 Jul; 15(4):400-7. PubMed ID: 18536580
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
Pulsipher MA; Bader P; Klingebiel T; Cooper LJ
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):62-71. PubMed ID: 19147081
[TBL] [Abstract][Full Text] [Related]
12. [Current therapeutic strategies in acute lymphoblastic leukemia in the adult].
Thomas X; Le QH
Bull Cancer; 2003 Oct; 90(10):833-50. PubMed ID: 14706913
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
Nabhan C; Coutré S; Hillmen P
Br J Haematol; 2007 Feb; 136(3):379-92. PubMed ID: 17129223
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now.
Goulden N; Virgo P; Grimwade D
Br J Haematol; 2006 Aug; 134(3):273-82. PubMed ID: 16848770
[TBL] [Abstract][Full Text] [Related]
17. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
19. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
Magrath I; Shanta V; Advani S; Adde M; Arya LS; Banavali S; Bhargava M; Bhatia K; Gutiérrez M; Liewehr D; Pai S; Sagar TG; Venzon D; Raina V
Eur J Cancer; 2005 Jul; 41(11):1570-83. PubMed ID: 16026693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
